| scholarly article | Q13442814 |
| P50 | author | Don Love | Q50112198 |
| Richard Faull | Q28101943 | ||
| P2093 | author name string | Emson PC | |
| Augood SJ | |||
| Faull RL | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| enkephalin | Q325101 | ||
| substance P | Q411041 | ||
| striatum | Q1319792 | ||
| P1104 | number of pages | 14 | |
| P304 | page(s) | 1023-1036 | |
| P577 | publication date | 1996-06-01 | |
| P1433 | published in | Neuroscience | Q15708571 |
| P1476 | title | Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study | |
| P478 | volume | 72 |
| Q38160307 | Advances in huntington disease drug discovery: novel approaches to model disease phenotypes |
| Q31096639 | Alterations in the mouse and human proteome caused by Huntington's disease |
| Q33703899 | Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease |
| Q35106821 | Biochemical and molecular studies using human autopsy brain tissue |
| Q42469950 | Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease |
| Q38342965 | Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys |
| Q42461333 | Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brain |
| Q33663335 | Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease |
| Q44662096 | Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis |
| Q45299575 | Discrimination, reversal, and shift learning in Huntington's disease: mechanisms of impaired response selection. |
| Q52690256 | Disrupted striatal neuron inputs and outputs in Huntington's disease. |
| Q36767264 | Drug targeting of dysregulated transcription in Huntington's disease |
| Q42477087 | Early effects of intrastriatal injections of quinolinic acid on microtubule-associated protein-2 and neuropeptides in rat basal ganglia |
| Q45291818 | Evidence for progression in frontal cortical pathology in late-stage Huntington's disease |
| Q73014588 | Exploration of motor cortex excitability in a diabetic patient with hemiballism-hemichorea |
| Q48372083 | Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain |
| Q60623896 | Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum |
| Q52535111 | Expression of the glutamate transporters in human temporal lobe epilepsy. |
| Q48462037 | Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia |
| Q40859661 | From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease |
| Q46486255 | GABA signalling: therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease |
| Q49106173 | Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus |
| Q30996882 | Gene expression profiling in the post-mortem human brain--no cause for dismay. |
| Q27023050 | Genetics and neuropathology of Huntington's disease |
| Q36016647 | Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease |
| Q83728053 | Huntington's Disease |
| Q35286098 | Huntington's Disease and Striatal Signaling. |
| Q37820343 | Huntington's disease and Group I metabotropic glutamate receptors |
| Q28141140 | Localization of calcium-binding proteins and GABA transporter (GAT-1) messenger RNA in the human subthalamic nucleus |
| Q45306356 | Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice |
| Q48125594 | Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABA(A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression |
| Q37776087 | Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease |
| Q27005950 | Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. |
| Q24605880 | Multiple Aspects of Gene Dysregulation in Huntington's Disease |
| Q37294750 | Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse |
| Q91972707 | Neurodegenerative Diseases - Is Metabolic Deficiency the Root Cause? |
| Q94594448 | New Synthetic 3-Benzoyl-5-Hydroxy-2H-Chromen-2-One (LM-031) Inhibits Polyglutamine Aggregation and Promotes Neurite Outgrowth through Enhancement of CREB, NRF2, and Reduction of AMPKα in SCA17 Cell Models |
| Q34273178 | Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease |
| Q36055312 | Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study |
| Q99638675 | Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice |
| Q35432364 | Proteomic Characterization of Cerebrospinal Fluid from Ataxia-Telangiectasia (A-T) Patients Using a LC/MS-Based Label-Free Protein Quantification Technology |
| Q45297228 | Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease |
| Q92319225 | Reduced nucleus accumbens enkephalins underlie vulnerability to social defeat stress |
| Q45299732 | Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. |
| Q36597920 | Selective neuronal degeneration in Huntington's disease |
| Q33831774 | Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity |
| Q36269123 | Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease |
| Q34573861 | Striosomes and mood dysfunction in Huntington's disease. |
| Q51420204 | Tachykinins increase [3H]acetylcholine release in mouse striatum through multiple receptor subtypes. |
| Q38663086 | The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers |
| Q38238474 | The expanding role for chromatin and transcription in polyglutamine disease. |
| Q34259043 | The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders |
| Q45300428 | The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease |
| Q38928744 | The role of the human globus pallidus in Huntington's disease. |
| Q33939097 | The selective vulnerability of striatopallidal neurons |
| Q45304764 | The ubiquitin conjugating enzyme Ube2W regulates solubility of the Huntington's disease protein, huntingtin. |
| Q33778522 | Transcriptional activation of REST by Sp1 in Huntington's disease models |
| Q33755822 | Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis |
| Q34001953 | Transcriptional dysregulation in Huntington's disease |
| Q31129663 | Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. |
| Q36752799 | Transcriptional signatures in Huntington's disease |
| Q34446513 | Triplet repeats, RNA secondary structure and toxic gain-of-function models for pathogenesis |
Search more.